- our experts
- Student Sphere
- Hotel & Travel
Drugs that affect the central nervous system (CNS) act on the brain and spinal cord and can be used to treat a variety of neurological and psychiatric disorders. Here are some examples of drugs that affect the CNS:
Analgesics: These drugs are used to relieve pain and include opioids, such as morphine and fentanyl, as well as non-opioid drugs, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs).
Anxiolytics and hypnotics: These drugs are used to treat anxiety and sleep disorders, respectively. Examples of anxiolytics include benzodiazepines, such as diazepam and alprazolam, while examples of hypnotics include zolpidem and eszopiclone.
Antidepressants: These drugs are used to treat depression and include selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, as well as tricyclic antidepressants, such as amitriptyline.
Antipsychotics: These drugs are used to treat psychotic disorders, such as schizophrenia, and include typical antipsychotics, such as chlorpromazine and haloperidol, as well as atypical antipsychotics, such as risperidone and olanzapine.
Stimulants: These drugs are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy and include drugs such as methylphenidate and amphetamines.
Mood stabilizers: These drugs are used to treat bipolar disorder and include lithium and valproic acid.
Sedatives: These drugs are used to induce sleep or reduce anxiety and include barbiturates, such as phenobarbital, and benzodiazepines, such as lorazepam.
Psychostimulants: These drugs are used to improve cognitive function, and include drugs such as modafinil and armodafinil.
Overall, drugs that affect the CNS play an important role in the treatment of neurological and psychiatric disorders, and can help improve outcomes and quality of life for patients with these conditions.
The global market for drugs affecting the central nervous system (CNS) is a significant segment of the pharmaceutical industry, given the high prevalence of neurological and psychiatric disorders and the increasing demand for effective treatments.
According to a report by Zion Market Research, the global CNS drugs market was valued at USD 77.2 billion in 2020 and is expected to reach USD 112.7 billion by 2028, growing at a CAGR of 4.7% during the forecast period (2021-2028).
The market for drugs affecting the CNS is segmented into various categories based on drug class, including anti-depressants, anti-psychotics, anti-epileptics, anxiolytics, and others. Anti-depressants are the largest segment of the market, followed by anti-psychotics.
The market is also segmented by geography, with North America and Europe accounting for the largest market shares due to the high prevalence of neurological and psychiatric disorders in these regions and the presence of major pharmaceutical companies. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing awareness and access to healthcare, as well as rising disposable income.
The demand for drugs affecting the CNS is driven by several factors, including the increasing prevalence of neurological and psychiatric disorders such as depression, anxiety, schizophrenia, and epilepsy. Additionally, the rise in healthcare expenditure and the growing focus on mental health are also contributing to the growth of the market.
Despite the promising growth prospects, the market for drugs affecting the CNS is facing some challenges, including the high cost of research and development, stringent regulatory requirements, and the increasing preference for non-pharmacological therapies.
Overall, the market for drugs affecting the CNS is expected to continue growing in the coming years, driven by the increasing demand for effective treatments for neurological and psychiatric disorders and advancements in drug development technology.
ALSO READ Drugs and Drug Targets Drug Discovery, Design and Development Pharmacokinetics and Pharmacodynamics Computer Aided Drug Design Drug Metabolism Pharmaceutical Biotechnology Combinatorial Chemistry Novel Drug Delivery Systems Formulations Natural Products Traditional Medicine Drug Repurposing and Drug Repositioning Precision Medicine Personalized Therapies Drug Development and Clinical Trials Biomarker Discovery and Development Biologics and Biosimilars Vaccines and Immunotherapies Steam Cells and Regenerative Medicine Drug Safety and Pharmacovigilance Pharmacogenomics Toxicology Rare Diseases Receptors as Target for Drug Discovery Drugs Affecting the Cardiovascular System Drugs Affecting the Central Nervous System Drugs Affecting Hormonal Systems Chemotherapeutic Agents Antibacterial Agents Antiviral Agents Anticancer Agents The Opioid Analgesics Anti-Ulcer Agents Non-Steroidal Anti Inflammatory Drugs Steroids Antibiotics Antineoplastic Agents Anthelmintics Sulphonamides Artificial Intelligence and Machine Learning in Drug Discovery and Development Genomics and Proteomics in Drug Discovery and Development Gene Therapy and Genome Editing in Treating Genetic Diseases Nanotechnology in Drug Delivery and Imaging Virtual and Augmented Reality in Drug Discovery and Development Patient Engagement and Patient-Centered Drug Development Big Data Analytics in Drug Discovery and Development
Precision Medicine Conferences Combinatorial Chemistry Conferences Medicinal Chemistry Conferences 2023 Europe Toxicology Conferences Traditional Medicine Conferences Drug Design Conferences Medicinal Chemistry Conferences 2023 Canada Medicinal Chemistry Conferences 2023 USA Natural Products Conferences Medicinal Chemistry Conferences 2023